09 Roche in Brief

Excellence in ScienceExcellence in Science

Our Business | Innovation is our answer to medical challenges. Our daily work is saving patients’ lives and helping millions of people around the world through excellence in science.

Focus on unsolved medical problemsFor more than 110 years Roche has played a pioneering role in healthcare. Today, as the world leader in in vitro diagnos-tics, we supply a wide range of diagnos-tic instruments and tests for rapid and reliable disease detection and monitoring by doctors, laboratories and patients themselves. As the world’s largest biotech company Roche has brought many highly effective drugs to market and become the world’s leading supplier of prescription drugs for cancer treatment. Our daily work focuses on disease areas where medical needs are great.

These include cancers, viral infections, metabolic and central nervous system dis-orders and inflammatory diseases. Roche is a pioneer in personalised healthcare: we aim to fit treatments as closely as possible to patients’ needs — to make healthcare better, safer and more cost-effective.

Our Business | Roche in Brief 1

Key figures 2009

Employees by operating division (full-time equivalents, FTE)

Pharma 48,341

Other 567

Diagnostics 25,967

Chugai 6,632

Sales by geographical area | in millions of CHF

Europe 18,286

Africa and Asia—Pacific 4,633

Japan 5,036

Latin America 2,940

North America 18,156

Sales by division | in millions of CHF

Pharma 38,996 (+11%)

Diagnostics 10,055 (+9%)

Italics = growth rates (in local currencies).

Employees by region (full-time equivalents, FTE)

North America 25,412

Africa 795

Latin America 4,930

Asia 14,169

Australia 891

Europe 35,310

Roche in Brief | Our Business2

Group performance at a glance

Operating profit* | in millions of CHF

9,18

9

11,7

30

14,4

68

13,8

96

15,0

12

0605 07 08 09

Operatingfree cash flow | in millions of CHF

6,82

8 8,56

0 10,6

71 12,3

78

15,7

22

0605 07 08 09

Net income | in millions of CHF

6,86

6

9,17

1

11,4

37

10,8

44

8,51

0

0605 07 08 09

Sales by division | in millions of CHF

27,2

68 |

8,24

3

33,2

94 |

8,74

7

36,7

83 |

9,35

0

35,9

61 |

9,65

6

38,9

96 |

10,0

55

0605 07 08 09

Pharmaceuticals Diagnostics

* Before exceptional items.

Our Business | Roche in Brief 3

For a full index of key facts and figures used in the report see: www.roche.com/key_facts_and_figures

Price development of non-voting equity security (Genussschein) | in CHF

150

100

050

200

250

Roche non-voting equity security Swiss Market Index (rebased)

200720062005 2008 2009

Pharmaceuticals | In 2009 demand for key medicines and efficiency gains resulted in double-digit increases in sales and operating profit. The division is focused on translating excel-lence in science into effective medicines for patients. It combines cutting-edge research at Roche, Genentech, Chugai and over 150 partners worldwide with global scale and reach in clinical development, manufacturing and commercial operations.

Core EPS | in CHF

7.84

9.86

11.8

5

11.0

4

12.1

9

0605 07 08 09

Dividend per share | in CHF

2.50

3.40

4.60 5.

00

6.00

0605 07 08 091

1 Proposed by the Board of Directors.

Pharmaceuticals pipeline | Focused on compounds with first-in-class or best-in-class potential

Project ID Project/Product Indication

Oncology

RG105 MabThera/Rituxan indolent NHL maint, 1st-line

RG340 Xeloda+Avastin adj colon cancer

RG340 Xeloda adj breast cancer

RG435 Avastin+MabThera diffuse large B cell lymphoma

RG435 Avastin adj colon cancer

RG435 Avastin prostate cancer

RG435 Avastin adj breast cancer HER2+

RG435 Avastin ovarian cancer, 1st-line

RG435 Avastin+Herceptin mBC, HER2+, 1st-line

RG435 Avastin adj NSCLC

RG435 Avastin met gastric cancer

RG435 Avastin adj breast cancer HER2–

RG435 Avastin adj BC, triple negative

RG435 Avastin mBC HER2–, combo hormonal therapy

RG435 Avastin ovarian cancer platinum-sensitive

RG435 Avastin mBC, 2nd-line

RG435 Avastin high-risk carcinoid

RG435 Avastin GBM, 1st-line

RG597 Herceptin SC formulation, BC HER2+

RG597 Herceptin adj BC HER2+, 2-yr treatment

RG1273 pertuzumab mBC HER2+

RG1415 Tarceva NSCLC EGFR mutation-positive, 1st-line

RG1415 Tarceva adj NSCLC

RG1415 Tarceva+Avastin NSCLC maint, 1st-line

RG7159 anti-CD20 huMAb chronic lymphocytic leukemia

RG7204 BRAF inh malignant melanoma

RG3502 trastuzumab-DM1 mBC HER2+, 2nd-line

Project ID Project/Product Indication

Inflammation and autoimmune disorders

RG105 MabThera/Rituxan ANCA-associated vasculitis

RG1569 Actemra/RoActemra JIA, systemic onset

RG1569 Actemra/RoActemra early rheumatoid arthritis

RG1594 ocrelizumab rheumatoid arthritis, PJD

RG3648 Xolair asthma, add-on therapy

Cardiovascular and metabolic diseases

RG1583 taspoglutide type 2 diabetes

RG1658 dalcetrapib dyslipidemia

Ophthalmology

RG3645 Lucentis diabetic macular edema

RG3645 Lucentis AMD, high dose

Others

RG3625 TNKase catheter clearance

Legend

Therapeutic protein, other biologic

Small molecule

Blue type First indication

Black type Additional indications

RG-No. Roche and/or Genentech managed

Phase III Large-scale studies in patients for statistical

confirmation of safety and efficacy

Selected abbreviations

adj adjuvant treatmentAMD age-related macular degenerationBC breast cancercombo combined withGBM glioblastoma multiformeHER2+ HER2-positiveHER2– HER2-negativehu humanisedinh inhibitorJIA juvenile idiopathic arthritisMAb monoclonal antibodymaint maintenance treatmentm, met metastatic (cancer)NHL non-Hodgkin’s lymphomaNSCLC non-small cell lung cancerPJD prevention of joint destructionSC subcutaneous

Phase III

Current as of January 2010

Pharmaceuticals | Roche in Brief 7

Sales | in mCHF

36,783 35,96138,996

0807 09

Operating profit | in mCHF

13,042 12,97414,154

0807 09

Number of employees

55,091 54,141 54,973

0807 09

Key figures

% change % change in In millions of CHF in CHF local currencies % of sales

Sales 38,996 8 11 100

— United States 14,805 6 5 38

— Western Europe 10,827 5 12 28

— Japan 4,765 43 29 12

— International (Asia—Pacific, CEMAI, 8,599 4 13 22

Latin America, Canada, Others)

Operating profit before exceptional items 14,154 9 15 36.3

Operating free cash flow 14,923 24 30 38.3

Research and development 8,896 13 13 22.8

Sales by region

United States 38% (+5%)

Asia—Pacific 5% (+20%)

Latin America 6% (+7%)

Other regions 3% (+12%)

CEMAI 8% (+13%)

Western Europe 28% (+12%)

Japan 12% (+29%)

Sales by therapeutic area

Oncology 53% (+8%)

Inflammatory and autoimmune diseases, transplantation 8% (–6%)

Central nervous system 2% (–5%)

Respiratory 3% (+8%)

Metabolic diseases, bone diseases 7% (–4%)

Infectious diseases 1% (–8%)

Cardiovascular diseases 3% (–2%)

Virology 15% (+79%)

Others 2% (–29%)

Renal anemia 3% (0%)

Ophthalmology 3% (+24%)

Italics = growth rates (local currencies).CEMAI: Central and Eastern Europe, Middle East, Africa,Central Asia, Indian Subcontinent.

Roche in Brief | Pharmaceuticals8

Top-selling pharmaceuticals — Roche Group Sales Product Active substance Indications in mCHF % change*

Avastin bevacizumab colorectal cancer, breast cancer, non-small 6,222 +21%

cell lung cancer, kidney cancer, glioblastoma

MabThera/Rituxan rituximab non-Hodgkin’s lymphoma, chronic 6,087 +6%

lymphocytic leukemia, rheumatoid arthritis

Herceptin trastuzumab HER2-positive breast cancer 5,266 +8%

Tamiflu oseltamivir treatment and prevention 3,200 +435%

of influenza A and B

Pegasys peginterferon alfa-2a hepatitis B and C 1,655 +5%

CellCept mycophenolate mofetil transplantation 1,576 –22%

NeoRecormon, epoetin beta anemia 1,560 –11%

Epogin

Tarceva erlotinib advanced non-small cell lung cancer, 1,304 +10%

advanced pancreatic cancer

Xeloda capecitabine colorectal cancer, breast cancer, stomach cancer 1,260 +7%

Lucentis** ranibizumab wet age-related macular degeneration 1,198 +24%

* In local currencies.** US sales.

Pharmaceuticals | Roche in Brief 9

Major regulatory approvals in 20091

Product Active substance Indication and/or dosage form Country

Avastin bevacizumab relapsed glioblastoma multiforme USA2, Switzerland

metastatic breast cancer; combination EU, Switzerland

with docetaxel

first-line metastatic renal cell carcinoma, USA

combination with interferon alfa-2a

unresectable advanced or recurrent non-squamous Japan

non-small cell lung cancer

MabThera/ rituximab relapsed or refractory chronic EU, Switzerland

Rituxan lymphocytic leukemia

first-line chronic lymphocytic leukemia EU

rheumatoid arthritis, guidance on retreatment USA

in patients with an inadequate response

to anti-TNF therapy

Actemra/ tocilizumab rheumatoid arthritis signs and symptoms EU, USA

RoActemra

Xeloda capecitabine advanced or refractory colorectal cancer, Japan

combination with oxaliplatin, with or without Avastin

1 Includes supplemental indications; updated to 8 January 2010.2 Accelerated approval (FDA).

Major regulatory filings in 20091

Product Active substance Indication and/or dosage form Country

Avastin bevacizumab relapsed glioblastoma multiforme Switzerland

first-line metastatic breast cancer, combination EU, USA, Japan,

with standard chemotherapy Switzerland

ED-71 eldecalcitol osteoporosis Japan

Epogin epoetin beta chemotherapy-induced anemia Japan

Herceptin trastuzumab advanced HER2-positive gastric cancer EU, Switzerland

Lucentis ranibizumab macular edema following retinal vein occlusion USA

MabThera/ rituximab rheumatoid arthritis — patients with an inadequate EU, Switzerland

Rituxan response to a disease-modifying antirheumatic drug;

prevention of joint damage

first-line chronic lymphocytic leukemia USA

relapsed or refractory chronic lymphocytic leukemia EU, USA,

Switzerland

RG744 methoxy polyethylene renal anemia Japan

(Mircera) glycol-epoetin beta

Tarceva erlotinib non-small cell lung cancer, first-line maintenance EU, USA,

after chemotherapy Switzerland

advanced pancreatic cancer Japan

Xeloda capecitabine adjuvant colon cancer, combination with oxaliplatin EU, Switzerland

1 Includes supplemental indications; updated to 8 January 2010.

Diagnostics | Sales again significantly outpaced the market, helped by strong uptake of new products. All five business areas launched major products during the year. Efforts to enhance efficiency contributed to higher operating profit in 2009. The division will expand these efforts in order to improve profitability further.

Diagnostics | Roche in Brief 11

Sales | in mCHF

9,350 9,656 10,055

0807 09

Operating profit | in mCHF

1,648

1,187 1,198

0807 09

Number of employees

23,06225,404 25,967

0807 09

Key figures

% change % change in In millions of CHF in CHF local currencies % of sales

Sales 10,055 4 9 100

— Professional Diagnostics 4,553 4 9 45

— Diabetes Care 2,969 0 6 29

— Molecular Diagnostics 1,183 2 5 12

— Applied Science 870 12 15 9

— Tissue Diagnostics 480 28 29 5

Operating profit 1,198 1 12 11.9

Operating free cash flow 1,152 92 102 11.5

Research and development 978 4 5 9.7

Top-selling diagnostics Sales Product line Market segment in mCHF % change*

Accu-Chek Diabetes management 2,969 +6%

cobas e modules, Modular Analytics, Elecsys Immunoassays 1,627 +19%

cobas c modules, Modular Analytics, Cobas Integra Clinical chemistry 1,275 +4%

Cobas AmpliPrep, Cobas TaqMan Virology 566 +4%

Cobas AmpliScreen, cobas TaqScreen Blood screening 314 +8%

CoaguChek meters Coagulation monitoring 293 +20%

Immunohistochemistry reagents Advanced tissue staining 281 +28%

MagNa Pure Systems, Light Cycler Systems Gene expression research 255 +35%

Sysmex analysers Hematology 141 +6%

454 Genome Sequencers DNA sequencing 139 +0%

* In local currencies.

Sales by region

Europe/Middle 53% (+9%)East /Africa

Japan 5% (+0%)

Asia—Pacific 10% (+25%)

Latin America 6% (+15%)

North America 26% (+4%)

Italics = growth rates (in local currencies).

Roche in Brief | Diagnostics12

Major product launches in 2009

Product Market

Professional Diagnostics

cobas c701 and c502 modules: First clinical chemistry modules for the cobas 8000 analyser EU series for high-throughput laboratories

cobas p 501 and cobas p 701: Automated post analytical sample storage and EUretrieval modules for bar-coded primary and secondary sample tubes

Sysmex XT-4000i: Hematology analyser for mid- to high-volume testing Contractual territories in EMEA

Immunoassays for PlGF (placenta growth factor) and SFlt1 EU (soluble fms-like tyrosine kinase 1): Diagnosis of preeclampsia

Immunoassay for anti-CCP (anti-cyclic citrullinated peptide antibody): USDiagnosis of rheumatoid arthritis

Immunoassay for IL-6 (interleukin-6): Aid in managing critically ill patients and monitoring EUcourse of disease

High-sensitivity immunoassay for troponin T: Diagnosis of heart attack EU, USand cardiac risk stratification

Immunoassay for troponin I: Prediction of mortality risk in patients with acute EUcoronary syndrome, diagnosis of heart attack and cardiac risk stratification

Diabetes Care

Accu-Chek Aviva Nano and Accu-Chek Performa Nano: Sleeker versions of the Accu-Chek EUAviva and Accu-Chek Performa meters offering an enhanced feature set

Accu-Chek Active: New version of existing system, featuring extended memory and EUa number of fail-safe capabilities

Accu-Chek Mobile: Integrated lancing and blood glucose monitoring device employing EUa unique ‘no strip’ technology

Accu-Chek Combo: Interactive diabetes management system combining an insulin pump EUand a blood glucose meter

Molecular Diagnostics

CT/NG test on cobas 4800 system: Detection of Chlamydia trachomatis and EUNeisseria gonorrhoeae

HPV test on cobas 4800 system: Detection of human papillomavirus EU

LightCycler MRSA Advanced Test: Identification of carriers of methicillin-resistant EUStaphylococcus aureus

TheraScreen EGFR 29 mutation test: Aids doctors in determining patients’ suitability EUfor certain cancer therapies

Applied Science

LightCycler 1536 system: High-throughput quantitative PCR analysis Worldwide

MagNa Pure 96 system: High-throughput system for preparing nucleic acid samples Worldwide

NimbleGen MS 200 scanner: High-resolution microarray scanner for use with WorldwideNimbleGen HD2 high-density microarrays

xCELLigence RTCA DP system: Medium-throughput system for real-time non-invasive Worldwidecell analysis

Tissue Diagnostics

INFORM EGFR DNA Probe: Quantitatively detects EGFR gene expression using silver EMEA, APACchromogenic in situ hybridisation (SISH)

CONFIRM anti HER2/neu Primary Antibody: Qualitative detection of protein over-expression EMEA, APACin breast and gastric tissue samples

INFORM HER2 DNA Probe: Detects HER2 gene status in breast and gastric EMEA, APACtissue samples

BenchMark Ultra: Advanced staining system with continuous and random processing EU, LATAM, Jand STAT capabilities

BenchMark XT: Fully automated instrument for advanced staining LATAM, APAC

Symphony: Instrument for primary staining EU

Vantage Information Solution: Workflow information management system for the anatomical EUpathology laboratory

EU = European Union; EMEA = Europe, Middle East and Africa; APAC = Asia—Pacific; LATAM = Latin America; US = United States; J = Japan.

Diagnostics | Roche in Brief 13

Major product launches planned for 20101

Product Market

Professional Diagnostics

cobas e 602 module: Immunoassay module for the cobas 8000 modular analyser series EU, USfor high-volume laboratories

cobas c 701 and cobas c 502 modules: Clinical chemistry modules for the cobas 8000 modular USanalyser series

cobas c 702 module: Advanced clinical chemistry module for the cobas 8000 modular EUanalyser series

cobas p 501 and cobas p 701: Automated post analytical sample storage and retrieval modules USfor bar-coded primary and secondary sample tubes

cobas b 123: Benchtop multiparameter analyser for use in critical care settings at the point EUof care

Eight Elecsys immunoassays in the US; six in the EU EU, US

Diabetes Care

Accu-Chek Aviva Nano: Sleeker version of the Accu-Chek Aviva meter offering USan enhanced feature set

Accu-Chek Mobile: Integrated lancing and blood glucose monitoring device Additional EUemploying a unique ‘no strip’ technology markets, APAC

Accu-Chek Combo: Interactive insulin delivery system combining an insulin pump Additional EUand a blood glucose meter markets, APAC, US

Molecular Diagnostics

LightCycler MRSA Advanced Test: Identification of carriers of methicillin-resistant USStaphylococcus aureus

Cobas AmpliPrep/Cobas TaqMan CMV: Viral load monitoring test to improve EUthe management of cytomegalovirus disease

cobas TaqScreen DPX Test: Blood Screening test designed to simultaneously provide EUa quantitative result for parvovirus B19 and a qualitative result for hepatitis A virus

Cobas AmpliPrep/Cobas TaqMan HIV-1 v2: Second-generation test enabling detection USof two separate regions of the HIV-1 genome

Cobas TaqMan 48 HIV v2: Manual sample preparation option for customers EUwith a low-volume workload

Applied Science

GS Junior System: Next-generation DNA sequencing system for smaller laboratories Worldwide

NimbleGen CGX-6 multiplex arrays: Microarrays for high-resolution analysis Worldwideof chromosomal abnormalities

xCELLigence RTCA HT instrument: Automated high-throughput real-time cell analyses Worldwideand screening

SeqCap EZ Exome v.2: In-solution enrichment capture technology for targeted Worldwidenext-generation sequencing

Next-generation ultra-high density NimbleGen microarrays Worldwide

Tissue Diagnostics

Dual colour/dual hapten in situ hybridisation (ISH) kit: For use with all molecular markers, EUspecifically to support HER2 testing

Anti-HER2 neu primary antibody and HER2 DNA probe: For assessing likelihood EUof response to Herceptin treatment in both breast and gastric cancer patients

BenchMark GX: Low-volume advanced tissue staining platform that automates EU, APACall slide processing steps from baking to staining

Molecular probes targeting the enzyme TOP2A and cell surface receptor IGF1R: EUFor use as an aid in diagnosing and managing breast and lung cancer

Discovery Ultra platform: For immunohistochemistry (IHC) and in situ hybridisation (ISH) US, EU, APAC, research, offering significant improvements in ease of use, workflow and flexibility Japan, LATAM

1 Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors.EU = European Union; EMEA = Europe, Middle East and Africa; APAC = Asia—Pacific; LATAM = Latin America; US = United States.

Corporate Responsibility | Our goal is to develop products and services that address unmet medical needs, improve patients’ health and quality of life and are of real value to society. We conduct our business in a responsible, sustainable manner that respects the needs of the individual, society and the en-vironment.

Corporate Responsibility | Roche in Brief 15

People

Our history of achieving our business goals and excelling in science and inno-vation is a result of consistently employing the best people — people who are passio-nate about making a difference to patients’ lives; people who lead and drive change; people who live our corporate values — integrity, courage and passion. We keep our employees engaged and performing at the highest level by creating a working environment in which everyone feels valued and respected; where they can develop to their fullest potential and can make their own mark. Our progress in achieving this is illustrated by our consis-tent ranking as an Employer of Choice.

Safety, security, health and environmental protectionProtection of the environment and con-servation of resources is a key concern at Roche. We take safety, security, health and environmental matters (SHE) into consideration in all our activities, and they are handled with the same sense of respon-sibility, and just as methodically, as issues concerning quality, productivity and cost-efficiency. Careful use of resources with mi-nimal environmental impact is an important element in sustainable development.

Sustainability

In brief

In our Corporate Principles we make the commitment to maintain high ethical and social standards in our business dealings, in our approach to medical science, in our efforts to protect the environment and to ensure good citizenship. We maintain these standards by adhering to local, national and international laws and regulations, by cooperating with authorities and by proactive dialogue with stake-holders.

Patients

Within our businesses — pharmaceuticals and diagnostics — we prioritise in areas of significant unmet need where we have the expertise to make a difference. Our aim is to develop new and improved medicines and diagnostic tests offering significant benefits over existing options, with a focus on personalised healthcare. This means patients can lead longer and better lives because they receive treatments that more effectively prevent and cure disease, allevi-ate symptoms and hasten recovery.

Society

Our support for communities focuses on programmes and areas that are aligned with our business model. We believe we can enhance the innovation, sustainabi-lity and impact of our business through appropriate donations, sponsorship and employee volunteering. This inspires and motivates our staff and ensures Roche remains a committed corporate citizen.

Roche in Brief | Corporate Responsibility16

Economic and business performance | in millions of CHF

2009 2008 2007

Sales (mCHF) 49,051 45,617 46,133

Research and development (mCHF) 9,874 8,845 8,385

Research and development as % of sales 20.1% 19.4% 18.2%

Operating profit before exceptional items (mCHF) 15,012 13,896 14,468

Operating profit margin 30.6% 30.5% 31.4%

Net financial income (mCHF) –1,668 236 834

Net Income (mCHF) 8,510 10,844 11,437

Core earnings per share (CHF) 12.19 11.04 11.85

Operating free cash flow 15,722 12,378 10,671

Operating free cash flow as % of sales 32.1% 27.1% 23.1%

Net assets (mCHF) 9,414 53,822 53,443

Net cash (debt) (mCHF) –23,867 16,682 17,336

Equity ratio 12.63% 70.70% 68.2%

Increasing value for our shareholders and investors

Dividend per share (CHF)1) 6.00 5.00 4.60

Dividend (mCHF)1) 5,175 4,313 3,968

Dividend as % of sales 10.6% 9.5% 8.6%

Payout Ratio 53% 49% 41%

Price of non-voting equity security

(Genussschein) at 31st of December (CHF) 175.80 162.50 195.60

Market capitalization (CHF billions) 151 141 171

Total Shareholder Return (TSR) at 31st of December 12% –16.0% –9.8%

Dow Jones World and FTSE4Good sustainability indexes Leader Included Included

Access to healthcare & patients benefits

Number of major regulatory approvals received 13 14 18

Number of major regulatory filings 23 12 14

Patients actively participating in clinical trials2) 269,895 235,420 201,752

Patients benefiting from Patient Assistance Programs

(US only) 40,000 38,000 34,480

Number of phase I—III clinical trials at 31st of December 111 119 108

Number of clinical trial protocols (Phase I—IV) published 649 574 480

% of all HIV/AIDS patients living in countries eligible

for no-profit Roche ARV medicines 68% 68% 70%

% of all HIV/AIDS patients living in countries eligible

for reduced-price Roche ARV medicines 83% 83% 86%

Technology Transfer Initiative (TTI) agreements

with companies covering sub-Saharan Africa

and the least developed countries (LDCs) 13 10 9

Key performance indicators of the Roche Group

Corporate Responsibility | Roche in Brief 17

Commitment to our employees

Number of employees (full-time equivalent — FTE) 81,507 80,080 78,604

Growth in full-time equivalent employees 1,427 1,476 4,232

Total employees’ remuneration (mCHF) 12,080 11,129 10,767

Total employees’ remuneration as % of sales 24.6% 24.4% 23.3%

Percentage of women in total workforce 46% 46% 45%

Percentage of women in management positions 37% 37% 32%

Staff turnover (fluctuation) 7% 9.9% 8.7%

Average number of training hours per employee 26 29 34.5

Numbers of Employees on Roche secondment 4 2 3

Percentage of eligible employees purchased shares

through Roche CONNECT 37% 36% 36%

Roche’s position in Science magazine’s top employers

in the biotech and pharmaceutical industries 17th 6th 18th

Genentech’s position in Science magazine’s top employers

in the biotech and pharmaceutical industries 1st 1st 2nd

Commitment to society and the communities we operate in

Income taxes (mCHF) 2,870 3,305 3,867

Income taxes as % of sales 5.9% 7.2% 8.4%

Community support by area:

— Humanitarian and social projects 75% 86% 85.5%

— Science and education 17% 11% 11.2%

— Arts and culture 5% 2% 1.8%

— Community and environment 3% 1% 1.5%

Safety, health and environmental protection

Investments in SHE (mCHF) 159 218 215

Operating costs for SHE (mCHF) 294 295 306

Roche Accident Rate 0.074 0.078 0.076

Occupational accidents 392 474 482

Occupational accidents per million working hours 2.92 3.42 3.46

Occupational illnesses 227 270 311

Eco-Efficiency Rate 84.02 77.95 67.19

eco-balance 4.6 4.95 5.15

Total energy consumption (TJ/year) 13,898 13,662 13,664

Total energy consumption (TJ/year per mCHF sales) 0.283 0.299 0.296

Greenhouse gas emissions (tonnes CO2 equivalents) 1,053,118 1,062,114 1,052,407

Greenhouse gas emissions (tonnes CO2 equivalents

per mCHF sales) 21.47 23.28 22.81

NOx (t/year) 286 193 169

SO2 (t/year) 9 10 12

Volatile organic compounds (VOCs) (t/year) 177 213 240

Particulate matter (t/year) 27 27 25

Water consumption (million cubic meters per year) 2.8 2.4 2.30

Water consumption (cubic meters per year per mCHF sales) 56.12 51.9 50.3

Total organic carbon (TOC) (t/year) 154 592 641

Heavy metals (kg/year) 426 545 605

Chemical waste (t/year) 27,605 31,295 38,167

General waste (t/year) 19,828 42,823 17,480

1) For the year 2009 as proposed by the Board of Directors.2) Clinical development phases I to IV.Figures for 2007 as in Annual Report 2008.

Roche in Brief | Our Business18

Progress and achievements in 2009

Responsible practices Named Healthcare Super Sector Leader in Dow Jones Sustainability Indexes.

Reselected for the DJSI World and STOXX indices and the FTSE4Good index.

Produced five new position papers on: stem cells and cloning; nanotechnology;

biobanks; personalised healthcare; and the value of our products and services.

Launched Group-wide phone line and web-based system for reporting violations

of our Code of Conduct.

Developed new Supplier Code of Conduct to describe our requirements in ethics;

safety, health an environment; innovation; supplier diversity; economic

sustainability and social responsibility.

Patients and access OneWorld Health completed first screening of Roche’s chemical compound

to healthcare library to find new drugs to treat diarrhea.

Joined a public-private partnership with Novo Nordisk and the World Diabetes

Foundation to improve care for children with diabetes in Africa.

Donated 5.65 million additional Tamiflu courses to replenish WHO stockpiles.

Launched Tamiflu Reserves Program to increase access in developing countries.

Provided free treatment to 40,500 patients in the US through

the Roche/Genentech Access programmes.

Disclosed all financial and in-kind support for patient organisations

on our website.

People Global employee Listening to You survey resulted in 91% of employees

expressing job satisfaction at Roche.

Genentech voted Science magazine’s top employer for the seventh time.

Rolled out globally aligned performance management and compensation

principles and began to align these between Genentech and Roche.

Expanded global leadership programme portfolio, providing key programmes

at every stage in the leadership development and talent pipeline.

Society Launched new Corporate policy on philanthropic donations and non-commercial

sponsorship.

Launched cancer awareness campaign in rural South Africa, which trains nursing

staff, offers free screening for breast, cervical and prostate cancers, and raises

awareness of the disease.

Safety, health and Produced manual on energy efficient design standards for our buildings.

environmental protection Launched e-learning programme on safety, security, health and environmental

protection for all employees.

Launched the Roche Environmental Awareness in Chemical Technology (REACT)

programme to reduce the environmental impact of our products.

No. of Security securities Listing Trading Symbol CUSIP/ISIN

Voting share 160,000,000 SIX Swiss Exchange SIX Swiss Exchange RO CH0012032113

Non-voting equity 702,562,700 SIX Swiss Exchange virt-x ROG CH0012032048

security (NES)

ADR Note a) OTCQX OTCQX RHHBY 771195104

Note a) The number of ADRs in issue varies depending on demand and conversion in and out of the underlying non-voting equity security (NES).

Published byF. Hoffmann-La Roche Ltd4070 Basel, SwitzerlandTel. + 41 (0)61 688 11 11Fax + 41 (0)61 691 93 91

Media OfficeGroup Communications4070 Basel, SwitzerlandTel. + 41 (0)61 688 88 88Fax + 41 (0)61 691 27 75

Investor Relations 4070 Basel, SwitzerlandTel. + 41 (0)61 688 88 80Fax + 41 (0)61 691 00 14

World Wide Webwww.roche.com

Corporate Sustainability CommitteeTel. + 41 (0)61 688 40 18E-mail: corporate.sustainability@roche.com

To order publicationsTel. + 41 (0)61 688 83 39Fax + 41 (0)61 688 43 43E-mail: basel.webmaster@roche.com

Cautionary statement regarding forward-looking statements

Roche in Brief contains certain forward-looking state-

ments. These forward-looking statements may be identi-

fied by words such as ‘believes’, ‘expects’, ‘anticipates’,

‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’

or similar expressions or by discussion of, among other

things, strategy, goals, plans or intentions. Various factors

may cause actual results to differ materially in the future

from those reflected in forward-looking statements

contained in Roche in Brief, among others: (1) pricing

and product initiatives of competitors; (2) legislative and

regulatory developments and economic conditions;

(3) delay or inability in obtaining regulatory approvals or

bringing products to market; (4) fluctuations in currency

exchange rates and general financial market conditions;

(5) uncertainties in the discovery, development or mar-

keting of new products or new uses of existing products,

including without limitation negative results of clinical

trials or research projects, unexpected side effects of

pipeline or marketed products; (6) increased government

pricing pressures; (7) interruptions in production; (8) loss

of or inability to obtain adequate protection for intellectual

property rights; (9) litigation; (10) loss of key executives

or other employees; and (11) adverse publicity and news

coverage.

The statement regarding earnings per share growth is not

a profit forecast and should not be interpreted to mean

that Roche’s earnings or earnings per share for 2009 or

any subsequent period will necessarily match or exceed

the historical published earnings or earnings per share

of Roche.

Roche in Brief is published in English and is issued by

F. Hoffmann-La Roche Ltd, Basel, Group Communications.

Printed on non-chlorine bleached, FSC-certified paper.

F. Hoffmann-La Roche Ltd 4070 Basel, Switzerland

© 2010

All trademarks are legally protected.

www.roche.com

7 000 847